Agency for Health Care Administration:
SB 1588 makes several changes to statutes administered or affected by the Agency for Health Care Administration. First, it repeals the State Consumer Health Information and Policy Advisory Council, removing a formal advisory body that currently assists the Florida Center for Health Information and Transparency. The bill also revises Florida law governing assisted living and memory care by creating a statutory definition of “memory care services” and setting new operational, staffing, disclosure, and contract requirements for facilities that advertise or provide such services.
Under the memory care provisions, facilities that hold themselves out as memory care providers would have to adopt policies on admission criteria and care needs, provide memory-specific activities, keep accurate resident logs, maintain at least one awake, trained, CPR/first-aid-certified staff member at all times, and notify physicians and resident representatives when a resident’s condition worsens. Resident contracts would have to identify the memory care services provided and any extra charges. Facilities advertising special care for Alzheimer’s disease, dementia, or other memory-related disorders would also have to disclose what distinguishes that care and keep those materials available for review by the agency during license renewal.
The bill further repeals section 429.178, Florida Statutes, which currently addresses special care for persons with Alzheimer’s disease or related disorders, and replaces it with the new memory care framework effective January 1, 2026. In addition, it amends a separate insurance-related statute on bone marrow transplant coverage by deleting the Agency for Health Care Administration’s rulemaking authority and the detailed advisory panel process that currently guides which transplant procedures are considered nonexperimental for coverage purposes.
Overall, the bill’s impact would be to tighten and modernize regulation of memory care facilities while reducing one health-information advisory structure and changing how certain insurance coverage rules are developed. It would affect assisted living facilities, memory care units, residents and families seeking dementia-related care, and the agency’s oversight responsibilities. The bill appears to have been intended as a consumer-protection and transparency measure for memory care, but it also imposes new compliance obligations on providers.
No committee transcripts or recorded votes were provided, and the bill ultimately died in the Senate Health Policy committee. Based on the text alone, the measure appears policy-driven and regulatory rather than controversial in tone, but the new staffing, disclosure, and operational mandates likely would have drawn attention from assisted living and memory care providers because of the added compliance burden. The repeal of the advisory council and the bone marrow transplant rulemaking provisions may also have raised questions about reducing stakeholder input in health policy decisions.
The bill would amend sections 408.05, 429.177, and 627.4236 of the Florida Statutes and repeal section 429.178, substantially restructuring state law on memory care and certain health policy administration. It would eliminate the State Consumer Health Information and Policy Advisory Council, replace existing Alzheimer’s/special care provisions with a new memory care services framework, and alter the process for determining covered bone marrow transplant procedures by removing specified rulemaking and advisory-panel requirements. The primary affected parties would be assisted living facilities, memory care providers, residents with dementia or Alzheimer’s disease, their families, and the Agency for Health Care Administration.
No committee debate or vote record was provided, so there is no documented floor or committee sentiment to summarize. From the bill text, the policy direction appears generally consumer-protective and oversight-oriented, especially regarding memory care transparency and staffing. At the same time, the measure would impose new operational requirements on facilities and reduce some existing advisory and rulemaking structures, suggesting a mix of support for stronger standards and possible concern from regulated providers and stakeholders who favor more flexible administration.
The most likely points of contention are the new compliance requirements for memory care providers, including awake staffing, training, documentation, resident notification, and contract disclosure obligations, which could increase costs and operational burdens for assisted living facilities. Another potential issue is the bill’s replacement of the existing Alzheimer’s/special care statute with a new memory care framework, which may affect how facilities market services and how the state enforces standards. Finally, the repeal of the consumer health advisory council and the removal of rulemaking authority for bone marrow transplant coverage could be viewed as reducing stakeholder participation in health policy decisions, a point that may concern consumer advocates, insurers, or medical groups.